Advancing Biopharmaceutical Innovation with Creative Capital Solutions

HealthCare Royalty is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products.

Royalty Monetization

EXPLORE

Corporate Financing

EXPLORE

$6.3B

Raised in cumulative capital commitments

$6.3B

Raised in cumulative capital commitments and offices in NY Metro Area, CA, MA and UK

NY

New York Metro Area

CA

San Francisco

MA

Boston

UK

London

34

34

Team members

MEET OUR TEAM

Interview with Neil McFarlane, Former CEO, Adamas Pharmaceuticals

Interview with Gary Lyons, HCRx Senior Advisor

Interview with Dennis Lanfear, President, CEO and Chairman, Coherus BioSciences

Interview with Dr. Greg Went, Former Chairman & CEO, Adamas Pharmaceuticals (December 2017)

Interview with Julie McHugh, HCRx Senior Advisor

Interview with Julie Anne Smith, Former President and CEO, Raptor Pharmaceuticals

Interview with Dr. Robert Langer, HCRx Senior Advisor

Interview with Mardi Dier, Former CFO, Portola, HCRx Board Member

Interview with Marc Kozin, HCRx Board Member

Interview with Nat Ricciardi, HCRx Senior Advisor

Spotlight
Latest News

uniQure Announces Sale of Royalty Interest in HEMGENIX ® for Up To $400 Million

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

More News